Akin Gump Strauss Hauer & Feld
Akin Gump Strauss Hauer & Feld filed a Q2 report for Biotechnology Innovation Organization on July 20, 2026, reporting $60,000 in lobbying income.
Lobbying for Biotechnology Innovation Organization
-
MARA LEFEVRE New on this filingPreviously held: Leg. Asst., Sen. Hoeven (2025-2026); Leg. Aide, Sen. Hoeven (2025); Leg. Cor., Sen. Hoeven (2023-2024); Staff Asst., Sen. Hoeven (2022-2023); Intern, Sen. KCramer (2020).
Issues related to the Small Business Innovation Research Program in the Small Business Innovation and Economic Security Act (P.L. 119-83).
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases; Issues related to the biotech ecosystem, including most-favored-nation drug pricing; Issues related to PBM reform, PAHPA reauthorization; and PDUFA reauthorization.